The core elements in the Canadian Rheumatoid Arthritis Core Clinical Dataset were rated as important and feasible to collect by rheumatology care providers and people living with arthritis from across Canada.
This study aims to develop system-level performance measures for evaluating the care of patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.
Given the broad scope of the spillover effects of illness, it is important to characterize the variability in these outcomes to identify relationship types in which secondary impacts of illness are particularly important to include in health economic evaluations.
Patients with multi-morbid diabetes, arthritis, neurological, or long-term mental health problems have significantly lower health-related quality of life (HRQoL) than other people. The associations of physical health with HRQoL were stronger in the presence of long-term mental health problems.
Estimates the minimally important difference for a fatigue visual analog scale (VAS) using patient-reported anchors (fatigue, pain, and overall health). This information can aid in interpreting fatigue VAS in day-to-day care in clinical practice.
The authors conducted a prospective cohort study of rates of change in disease-modifying antirheumatic drug (DMARD) and/or systemic corticosteroid drug or dose for 568 patients with rheumatoid arthritis (RA) across 6,159 clinical encounters within 12 months to examine how changes in clinical specifications change adherence.
The evidence for effects of omega-3 fatty acids on outcomes in the conditions assessed varies greatly. Omega-3 fatty acids appear to reduce serum triglycerides among type II diabetics, but have no effect on total cholesterol, HDL cholesterol, and LDL cholesterol.